EUVIMEDEUVIMED entdecken
Open Access

SOX2 transactivates NRF2 to promote carboplatin resistance in lung squamous cell carcinoma

Hanfei Gao, Chaomei Li, Jie Sun, Liyuan Deng, Jia Li, Zhiqiang Wu, Hu Chen

Acta Biochimica et Biophysica Sinica · 2025

DOI: 10.3724/abbs.2025228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2025. Verfasst von Hanfei Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, School of Clinical Medicine and The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, SOXB1 Transcription Factors, Carboplatin, Drug Resistance, Neoplasm. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung squamous cell carcinoma (LUSC) remains a major therapeutic challenge because of its pronounced resistance to chemotherapy, particularly carboplatin. In this study, we investigate the role of SOX2, a lineage-survival oncogene, in mediating carboplatin resistance in LUSC. We demonstrate that SOX2 is highly expressed in LUSC and is significantly associated with poor prognosis. Our results show that SOX2 directly transactivates the expression of NRF2, a master regulator of cellular redox homeostasis, thereby increasing glutathione (GSH) synthesis and protecting cells from carboplatin-induced oxidative stress. Pharmacological or genetic inhibition of NRF2 effectively abrogates SOX2-mediated carboplatin resistance both in vitro and in vivo, resensitizing LUSC cells to chemotherapy. These findings highlight SOX2 as a critical redox regulator that modulates NRF2 signaling to promote carboplatin resistance in LUSC. The identification of the SOX2-NRF2 axis as a potential therapeutic target suggests that NRF2 inhibition may represent a promising strategy to overcome chemoresistance in LUSC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2SOXB1 Transcription FactorsCarboplatinDrug Resistance, NeoplasmLung NeoplasmsCarcinoma, Squamous CellHumansAnimalsCell Line, TumorMiceFemaleMaleAntineoplastic AgentsGene Expression Regulation, NeoplasticMice, NudeOxidative Stress

Stichwörter der Autor:innen

LUSCNRF2ROSSOX2carboplatin resistance

Substanzen

NF-E2-Related Factor 2SOXB1 Transcription FactorsCarboplatinSOX2 protein, humanNFE2L2 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, School of Clinical Medicine and The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China.
  • Department of Anesthesia, School of Clinical Medicine and The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China.
  • Key Laboratory of Geriatic Respiratory Diseases of Sichuan Higher Education Institute, Chengdu 610500, China.

Zitieren

APA

Gao, H., Li, C., Sun, J., Deng, L., Li, J., Wu, Z., & Chen, H. (2025). SOX2 transactivates NRF2 to promote carboplatin resistance in lung squamous cell carcinoma. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025228

Vancouver

Gao H, Li C, Sun J, Deng L, Li J, Wu Z, et al. SOX2 transactivates NRF2 to promote carboplatin resistance in lung squamous cell carcinoma. Acta Biochimica et Biophysica Sinica. 2025. doi:10.3724/abbs.2025228

BibTeX
@article{Gao2025,
  author = {Gao, Hanfei and Li, Chaomei and Sun, Jie and Deng, Liyuan and Li, Jia and Wu, Zhiqiang and Chen, Hu},
  title = {SOX2 transactivates NRF2 to promote carboplatin resistance in lung squamous cell carcinoma},
  journal = {Acta Biochimica et Biophysica Sinica},
  year = {2025},
  doi = {10.3724/abbs.2025228}
}
Kostenlos starten →